A Phase II trial investigated combination treatments of dabrafenib and trametinib in chemotherapy-pretreated patients diagnosed with BRAF V600E-mutated NSCLC and reported an ORR of 63% and a median PFS of 9.7 months in 52 evaluable patients [11]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.